|
1
|
Antun AG, Gleason S, Arellano M, et al:
Epsilon aminocaproic acid prevents bleeding in severely
thrombocytopenic patients with hematological malignancies. Cancer.
119:3784–3787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dhir A: Antifibrinolytics in cardiac
surgery. Ann Card Anaesth. 16:117–125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jankun J and Skrzypczak-Jankun E:
Plasminogen activator inhibitor with very long half-life (VLHL
PAI-1) can reduce bleeding in PAI-1-deficient patients. Cardiovasc
Hematol Disord Drug Targets. 13:144–150. 2013.PubMed/NCBI
|
|
4
|
Mosesson MW: Fibrinogen and fibrin
structure and functions. J Thromb Haemost. 3:1894–1904. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rau JC, Beaulieu LM, Huntington JA and
Church FC: Serpins in thrombosis, hemostasis and fibrinolysis. J
Thromb Haemost. 5:(Suppl 1). 102–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zorio E, Gilabert-Estellés J, España F,
Ramón LA, Cosín R and Estellés A: Fibrinolysis: the key to new
pathogenetic mechanisms. Curr Med Chem. 15:923–929. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dellas C and Loskutoff DJ: Historical
analysis of PAI-1 from its discovery to its potential role in cell
motility and disease. Thromb Haemost. 93:631–640. 2005.PubMed/NCBI
|
|
8
|
Cesarman-Maus G and Hajjar KA: Molecular
mechanisms of fibrinolysis. Br J Haematol. 129:307–321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Egelund R, Schousboe SL, Sottrup-Jensen L,
Rodenburg KW and Andreasen PA: Type-1 plasminogen-activator
inhibitor - conformational differences between latent, active,
reactive-centre-cleaved and plasminogen-activator-complexed forms,
as probed by proteolytic susceptibility. Eur J Biochem.
248:775–785. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jankun J, Yang J, Zheng H, Han FQ,
Al-Senaidy A and Skrzypczak-Jankun E: Remarkable extension of PAI-1
half-life surprisingly brings no changes to its structure. Int J
Mol Med. 29:61–64. 2012.PubMed/NCBI
|
|
11
|
Chorostowska-Wynimko J, Swiercz R,
Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel
form of the plasminogen activator inhibitor created by cysteine
mutations extends its half-life: relevance to cancer and
angiogenesis. Mol Cancer Ther. 2:19–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jankun J, Aleem AM, Selman SH, et al:
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1)
protects fibrin clots from tissue plasminogen activator-mediated
fibrinolysis. Int J Mol Med. 20:683–687. 2007.PubMed/NCBI
|
|
13
|
Jankun J, Keck R, Selman SH and
Skrzypczak-Jankun E: Systemic or topical application of plasminogen
activator inhibitor with extended half-life (VLHL PAI-1) reduces
bleeding time and total blood loss. Int J Mol Med. 26:501–504.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jankun J, Selman SH, Keck RW,
Łysiak-Szydłowska W and Skrzypczak-Jankun E: Very long half-life
plasminogen activator inhibitor type 1 reduces bleeding in a mouse
model. BJU Int. 105:1469–1476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jankun J, Skotnicka M, Łysiak-Szydłowska
W, Al-Senaidy A and Skrzypczak-Jankun E: Diverse inhibition of
plasminogen activator inhibitor type 1 by theaflavins of black tea.
Int J Mol Med. 27:525–529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jankun J and Skrzypczak-Jankun E: Yin and
yang of the plasminogen activator inhibitor. Pol Arch Med Wewn.
119:410–417. 2009.PubMed/NCBI
|
|
17
|
Jankun J, Aleem AM, Struniawski R,
Lysiak-Szydłowska W, Selman SH and Skrzypczak-Jankun E: Accelerated
thrombus lysis in the blood of plasminogen activator inhibitor
deficient mice is inhibited by PAI-1 with a very long half-life.
Pharmacol Rep. 61:673–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morimoto Y, Yoshioka A, Imai Y, Takahashi
Y, Minowa H and Kirita T: Haemostatic management of intraoral
bleeding in patients with congenital deficiency of alpha2-plasmin
inhibitor or plasminogen activator inhibitor-1. Haemophilia.
10:669–674. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schulman S: Pharmacologic tools to reduce
bleeding in surgery. Hematology Am Soc Hematol Educ Program.
2012:517–521. 2012.PubMed/NCBI
|
|
20
|
Makhija N, Sarupria A, Kumar Choudhary S,
Das S, Lakshmy R and Kiran U: Comparison of epsilon aminocaproic
acid and tranexamic acid in thoracic aortic surgery: clinical
efficacy and safety. J Cardiothorac Vasc Anesth. 27:1201–1207.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harrop SJ, Jankova L, Coles M, et al: The
crystal structure of plasminogen activator inhibitor 2 at 2.0 A
resolution: implications for serpin function. Structure. 7:43–54.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sharp AM, Stein PE, Pannu NS, et al: The
active conformation of plasminogen activator inhibitor 1, a target
for drugs to control fibrinolysis and cell adhesion. Structure.
7:111–118. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fergusson DA, Hébert PC, Mazer CD, et al:
BART Investigators: A comparison of aprotinin and lysine analogues
in high-risk cardiac surgery. N Engl J Med. 358:2319–2331. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Howell N, Senanayake E, Freemantle N and
Pagano D: Putting the record straight on aprotinin as safe and
effective: results from a mixed treatment meta-analysis of trials
of aprotinin. J Thorac Cardiovasc Surg. 145:234–240. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iribarren JL, Jimenez JJ, Hernández D, et
al: Postoperative bleeding in cardiac surgery: the role of
tranexamic acid in patients homozygous for the 5G polymorphism of
the plasminogen activator inhibitor-1 gene. Anesthesiology.
108:596–602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Racanelli AL, Diemer MJ, Dobies AC, Dubin
JR and Reilly TM: Comparison of recombinant plasminogen activator
inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit
model. Thromb Haemost. 67:692–696. 1992.PubMed/NCBI
|
|
27
|
van Meijer M, Smilde A, Tans G, Nesheim
ME, Pannekoek H and Horrevoets AJ: The suicide substrate reaction
between plasminogen activator inhibitor 1 and thrombin is regulated
by the cofactors vitronectin and heparin. Blood. 90:1874–1882.
1997.PubMed/NCBI
|
|
28
|
Fay WP, Parker AC, Condrey LR and Shapiro
AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency:
characterization of a large kindred with a null mutation in the
PAI-1 gene. Blood. 90:204–208. 1997.PubMed/NCBI
|
|
29
|
Jankun J and Skrzypczak-Jankun E: Bleeding
diathesis is associated with an A15T heterozygous mutation in exon
2 of the plasminogen activator inhibitor type 1. Exp Ther Med.
1:575–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mehta R and Shapiro AD: Plasminogen
activator inhibitor type 1 deficiency. Haemophilia. 14:1255–1260.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schleef RR, Higgins DL, Pillemer E and
Levitt LJ: Bleeding diathesis due to decreased functional activity
of type 1 plasminogen activator inhibitor. J Clin Invest.
83:1747–1752. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Genét GF, Ostrowski SR, Sørensen AM and
Johansson PI: Detection of tPA-induced hyperfibrinolysis in whole
blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in
healthy individuals. Clin Appl Thromb Hemost. 18:638–644. 2012.
View Article : Google Scholar : PubMed/NCBI
|
